Impact of Epstein-Barr Virus on Cervical Cancer Outcomes
Author Information
Author(s): Castro-Uriol Denisse, Vera Juana, Valcarcel Bryan, López-Ilasaca Marco, Yabar Alejandro, Cámara Anaís, Malpica Luis, Beltrán Brady
Primary Institution: Hospital Nacional Edgardo Rebagliati Martins, EsSalud, Lima, Peru
Hypothesis
Does Epstein-Barr virus infection affect clinical features and survival in locally advanced cervical cancer?
Conclusion
Females with cervical cancer and Epstein-Barr virus infection have similar clinical features and outcomes compared to those without the infection.
Supporting Evidence
- 21 out of 94 patients (22%) had a positive EBV status.
- 73% of patients received concurrent chemoradiotherapy as frontline treatment.
- The 5-year overall survival rate was 42% in the entire population.
- Patients with EBV-positive status had comparable survival rates to those without EBV.
Takeaway
This study looked at women with cervical cancer to see if having a virus called Epstein-Barr made a difference in their health. It found that it didn't really change how they did.
Methodology
A retrospective cohort study was conducted on 94 patients with cervical cancer, using RT-PCR to detect EBV and analyzing survival outcomes with Kaplan-Meier and Cox regression.
Potential Biases
Potential biases due to the retrospective nature and exclusion of patients with incomplete data.
Limitations
The study's retrospective design limited data completeness and generalizability, and HPV status was not directly assessed.
Participant Demographics
Median age was 55 years; most patients had ECOG scores of 0-1 and were multiparous.
Statistical Information
P-Value
0.490
Confidence Interval
95% CI: 33–55%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website